Ligand price target raised to $388 from $266 at BofA
BofA analyst Jason Zemansky raised the firm's price target on Ligand to $388 from $266 and keeps a Buy rating on the shares. Despite strong share performance, Ligand's growth opportunity remains underappreciated, with the XOMA acquisition expanding its royalty portfolio, diversification, scalability, and earnings poten